{"id":45753,"date":"2024-02-05T14:12:47","date_gmt":"2024-02-05T14:12:47","guid":{"rendered":"https:\/?p=45753"},"modified":"2024-02-05T14:12:47","modified_gmt":"2024-02-05T14:12:47","slug":"novo-nordisks-stock-rises-after-16-5b-catalent-deal","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/","title":{"rendered":"Novo Nordisk&#8217;s Stock Rises After $16.5B Catalent Deal"},"content":{"rendered":"<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/NVO\"><span style=\"font-weight: 400;\">Novo Nordisk (NVO: NYE<\/span><\/a><span style=\"font-weight: 400;\">) recently confirmed its acquisition of Catalent, a leader in drug development and manufacturing solutions, in a grand $16.5 billion deal. This event has raised questions among industry analysts and investors: specifically, whether or not it is a strategic maneuver or a high-stakes gamble for Novo Nordisk.<\/span><\/p>\n<p><!-- STA Widget BEGIN --><\/p>\n<div>\n<div class=\"sta-analyst-rating-widget-display\">\n<p><a style=\"text-decoration: none; color: #4b6db5 !important;\" href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/NVO\" target=\"_blank\" rel=\"noopener\">NVO Ratings<\/a> by Stock Target Advisor<\/p>\n<\/div>\n<p><script class=\"analyst-rating\" type=\"text\/javascript\" src=\"https:\/\/www.stocktargetadvisor.com\/assets\/js\/analyst_rating_widget.js\" data-symbol=\"NVO\" data-theme=\"wt_bg_trans\" data-uid=\"98718389865c0ec4c53b3f65c0ec4c53b40\" data-width=\"700\" >\n\t\t<\/script><\/p>\n<\/div>\n<h2><strong>Stock Target Advisor&#8217;s Assessment on this Deal:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.stocktargetadvisor.com\/\">Stock Target Advisor<\/a><\/strong> has issued a &#8220;Sell&#8221; recommendation for Novo Nordisk A\/S, with a projected price target of 0 USD for the next 12 months. Observing the market reactions and sentiments post this monumental Catalent acquisition, it&#8217;s critical to consider if this rating and forecast aligns with the ongoing trends.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Novo Nordisk seems to enjoy a &#8220;Strong Buy&#8221; recommendation from market analysts, with an average target price of 121 USD. It&#8217;s imperative to align these market sentiments with Stock Target Advisor&#8217;s assessment and the recent acquisition news.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Moreover, a thorough insight into the <strong><a href=\"https:\/\/www.stocktargetadvisor.com\/screens\/industries\/Gold\">Gold<\/a><\/strong> sector of the NYE exchange, its average returns pattern, leading stocks, and analyst insights would aid in assessing were Novo Nordisk A\/S stands in comparison.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Novo Nordisk: An Overview of Financial Performance<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">Novo Nordisk A\/S has outperformed many competitors in their sector, delivering an astonishingly high 1-year capital gains yield of 66.23%. This puts NVO in the 98.25th percentile of its sector. It&#8217;s worth exploring the factors contributing to such solid returns and their implications for an increasingly competitive market environment.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">When looking at Novo Nordisk&#8217;s 5-year growth chart, we see a steady climb. The company&#8217;s revenue growth sits at 58.42%, accompanied by robust earnings growth of 45.62%. These figures trigger a discussion of Novo Nordisk&#8217;s future trajectory and its unexplored potentials.<\/span><\/p>\n<p>&nbsp;<\/p>\n<h2><strong>Conclusion:<\/strong><\/h2>\n<p><span style=\"font-weight: 400;\">The acquisition of Catalent is a significant move that brings forth various long-term strategic growth potentials. Whether this move positions Novo Nordisk is a gamble, or a strategic maneuver is something only an astute, data-driven investor can discern.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NVO: NYE) recently confirmed its acquisition of Catalent, a leader in drug development and manufacturing solutions, in a grand $16.5 billion deal. This&#8230;<\/p>\n","protected":false},"author":17,"featured_media":42624,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-45753","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk&#039;s Stock Rises After $16.5B Catalent Deal<\/title>\n<meta name=\"description\" content=\"Novo Nordisk to acquire Catalent in a groundbreaking $16.5B deal, strengthening drug delivery capabilities. Shares surge in response.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk&#039;s Stock Rises After $16.5B Catalent Deal\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk to acquire Catalent in a groundbreaking $16.5B deal, strengthening drug delivery capabilities. Shares surge in response.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-02-05T14:12:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/11\/Novo-Nordisks-Wegovy-Data-Boosts-Stock-to-1-Month-High.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Muzzammil Ahmad\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/Muzzammil625\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Muzzammil Ahmad\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\"},\"author\":{\"name\":\"Muzzammil Ahmad\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\"},\"headline\":\"Novo Nordisk&#8217;s Stock Rises After $16.5B Catalent Deal\",\"datePublished\":\"2024-02-05T14:12:47+00:00\",\"dateModified\":\"2024-02-05T14:12:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\"},\"wordCount\":324,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\",\"name\":\"Novo Nordisk's Stock Rises After $16.5B Catalent Deal\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2024-02-05T14:12:47+00:00\",\"dateModified\":\"2024-02-05T14:12:47+00:00\",\"description\":\"Novo Nordisk to acquire Catalent in a groundbreaking $16.5B deal, strengthening drug delivery capabilities. Shares surge in response.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk&#8217;s Stock Rises After $16.5B Catalent Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8\",\"name\":\"Muzzammil Ahmad\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g\",\"caption\":\"Muzzammil Ahmad\"},\"description\":\"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.\",\"sameAs\":[\"https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/\",\"https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625\"],\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Stock Rises After $16.5B Catalent Deal","description":"Novo Nordisk to acquire Catalent in a groundbreaking $16.5B deal, strengthening drug delivery capabilities. Shares surge in response.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's Stock Rises After $16.5B Catalent Deal","og_description":"Novo Nordisk to acquire Catalent in a groundbreaking $16.5B deal, strengthening drug delivery capabilities. Shares surge in response.","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2024-02-05T14:12:47+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/11\/Novo-Nordisks-Wegovy-Data-Boosts-Stock-to-1-Month-High.jpg","type":"image\/jpeg"}],"author":"Muzzammil Ahmad","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/Muzzammil625","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"Muzzammil Ahmad","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/"},"author":{"name":"Muzzammil Ahmad","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8"},"headline":"Novo Nordisk&#8217;s Stock Rises After $16.5B Catalent Deal","datePublished":"2024-02-05T14:12:47+00:00","dateModified":"2024-02-05T14:12:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/"},"wordCount":324,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/","name":"Novo Nordisk's Stock Rises After $16.5B Catalent Deal","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2024-02-05T14:12:47+00:00","dateModified":"2024-02-05T14:12:47+00:00","description":"Novo Nordisk to acquire Catalent in a groundbreaking $16.5B deal, strengthening drug delivery capabilities. Shares surge in response.","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisks-stock-rises-after-16-5b-catalent-deal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk&#8217;s Stock Rises After $16.5B Catalent Deal"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/81d743c6903933055039390e1e98b5f8","name":"Muzzammil Ahmad","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d361e040abeba4e5b47d2fb7acae1401555042a5fc6862b11d7d01ac1722fed5?s=96&d=mm&r=g","caption":"Muzzammil Ahmad"},"description":"Muzzammil is a content writer at Stock Target Advisor. He has been writing stock news and analysis at Stock Target Advisor since 2023 and has worked in the financial domain in various roles since 2020. He has previously worked on an equity research firm that analyzed companies listed on the stock markets in the U.S. and Canada and performed fundamental and qualitative analyses of management strength, business strategy, and product\/services forecast as indicated by major brokers covering the stock.","sameAs":["https:\/\/www.linkedin.com\/in\/muzzammil-ahmad-a157b1190\/","https:\/\/twitter.com\/https:\/\/x.com\/Muzzammil625"],"url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/muzzammil\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/45753","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=45753"}],"version-history":[{"count":1,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/45753\/revisions"}],"predecessor-version":[{"id":45755,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/45753\/revisions\/45755"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/42624"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=45753"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=45753"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=45753"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}